These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 11703325)

  • 1. International prognostic scoring system and TP53 mutations are independent prognostic indicators for patients with myelodysplastic syndrome.
    Kita-Sasai Y; Horiike S; Misawa S; Kaneko H; Kobayashi M; Nakao M; Nakagawa H; Fujii H; Taniwaki M
    Br J Haematol; 2001 Nov; 115(2):309-12. PubMed ID: 11703325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents.
    Takahashi K; Patel K; Bueso-Ramos C; Zhang J; Gumbs C; Jabbour E; Kadia T; Andreff M; Konopleva M; DiNardo C; Daver N; Cortes J; Estrov Z; Futreal A; Kantarjian H; Garcia-Manero G
    Oncotarget; 2016 Mar; 7(12):14172-87. PubMed ID: 26871476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted next-generation sequencing in myelodysplastic syndromes and prognostic interaction between mutations and IPSS-R.
    Tefferi A; Lasho TL; Patnaik MM; Saeed L; Mudireddy M; Idossa D; Finke C; Ketterling RP; Pardanani A; Gangat N
    Am J Hematol; 2017 Dec; 92(12):1311-1317. PubMed ID: 28875545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel scoring system integrating molecular abnormalities with IPSS-R can improve the risk stratification in patients with MDS.
    Gu S; Xia J; Tian Y; Zi J; Ge Z
    BMC Cancer; 2021 Feb; 21(1):134. PubMed ID: 33549060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic evaluation of ALIP and CD34 immunostaining in IPSS-R subgroups of myelodysplastic syndromes.
    Xiong B; Nie Y; Tang Z; Xue M; Zuo X
    Pathology; 2017 Aug; 49(5):526-533. PubMed ID: 28669578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Configuration of the TP53 gene as an independent prognostic parameter of myelodysplastic syndrome.
    Horiike S; Kita-Sasai Y; Nakao M; Taniwaki M
    Leuk Lymphoma; 2003 Jun; 44(6):915-22. PubMed ID: 12854888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinct mutation profile and prognostic relevance in patients with hypoplastic myelodysplastic syndromes (h-MDS).
    Yao CY; Hou HA; Lin TY; Lin CC; Chou WC; Tseng MH; Chiang YC; Liu MC; Liu CW; Kuo YY; Wu SJ; Liao XW; Lin CT; Ko BS; Chen CY; Hsu SC; Li CC; Huang SY; Yao M; Tang JL; Tsay W; Liu CY; Tien HF
    Oncotarget; 2016 Sep; 7(39):63177-63188. PubMed ID: 27527853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic scoring systems for myelodysplastic syndromes (MDS) in a population-based setting: a report from the Swedish MDS register.
    Moreno Berggren D; Folkvaljon Y; Engvall M; Sundberg J; Lambe M; Antunovic P; Garelius H; Lorenz F; Nilsson L; Rasmussen B; Lehmann S; Hellström-Lindberg E; Jädersten M; Ejerblad E
    Br J Haematol; 2018 Jun; 181(5):614-627. PubMed ID: 29707769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical implications and prognostic value of TP53 gene mutation and deletion in patients with myelodysplastic syndromes].
    Huang HJ; Shi ZX; Li B; Qin TJ; Xu ZF; Zhang HL; Fang LW; Hu NB; Pan LJ; Qu SQ; Liu D; Cai YN; Zhang YD; Xiao ZJ
    Zhonghua Xue Ye Xue Za Zhi; 2019 Mar; 40(3):215-221. PubMed ID: 30929389
    [No Abstract]   [Full Text] [Related]  

  • 10. [Scoring analysis on prognosis of 63 patients with melodysplastic syndrome].
    Wei J; Chen Y
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Apr; 16(2):305-11. PubMed ID: 18426654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TP53 overexpression is an independent adverse prognostic factor in de novo myelodysplastic syndromes with fibrosis.
    Loghavi S; Al-Ibraheemi A; Zuo Z; Garcia-Manero G; Yabe M; Wang SA; Kantarjian HM; Yin CC; Miranda RN; Luthra R; Medeiros LJ; Bueso-Ramos CE; Khoury JD
    Br J Haematol; 2015 Oct; 171(1):91-9. PubMed ID: 26123119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutation status and burden can improve prognostic prediction of patients with lower-risk myelodysplastic syndromes.
    Jiang L; Luo Y; Zhu S; Wang L; Ma L; Zhang H; Shen C; Yang W; Ren Y; Zhou X; Mei C; Ye L; Xu W; Yang H; Lu C; Jin J; Tong H
    Cancer Sci; 2020 Feb; 111(2):580-591. PubMed ID: 31804030
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incorporation of mutations in five genes in the revised International Prognostic Scoring System can improve risk stratification in the patients with myelodysplastic syndrome.
    Hou HA; Tsai CH; Lin CC; Chou WC; Kuo YY; Liu CY; Tseng MH; Peng YL; Liu MC; Liu CW; Liao XW; Lin LI; Yao M; Tang JL; Tien HF
    Blood Cancer J; 2018 Apr; 8(4):39. PubMed ID: 29618722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The application of a new prognostic score system for 435 cases of primary myelodysplastic syndrome diagnosed with WHO classification].
    Wang XQ;
    Zhonghua Nei Ke Za Zhi; 2009 Aug; 48(8):633-7. PubMed ID: 19954053
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clonal hematopoiesis of indeterminate potential-associated mutations and risk of comorbidities in patients with myelodysplastic syndrome.
    Naqvi K; Sasaki K; Montalban-Bravo G; Alfonso Pierola A; Yilmaz M; Short N; Assi R; Jabbour E; Ravandi F; Kadia T; Pierce S; Takahashi K; Nogueras Gonzalez G; Kanagal-Shamanna R; Patel K; Soltysiak KA; Kantarjian HM; Garcia-Manero G
    Cancer; 2019 Jul; 125(13):2233-2241. PubMed ID: 30861111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes.
    Bejar R; Stevenson KE; Caughey BA; Abdel-Wahab O; Steensma DP; Galili N; Raza A; Kantarjian H; Levine RL; Neuberg D; Garcia-Manero G; Ebert BL
    J Clin Oncol; 2012 Sep; 30(27):3376-82. PubMed ID: 22869879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient-reported outcomes enhance the survival prediction of traditional disease risk classifications: An international study in patients with myelodysplastic syndromes.
    Efficace F; Cottone F; Abel G; Niscola P; Gaidano G; Bonnetain F; Anota A; Caocci G; Cronin A; Fianchi L; Breccia M; Stauder R; Platzbecker U; Palumbo GA; Luppi M; Invernizzi R; Bergamaschi M; Borin L; Di Tucci AA; Zhang H; Sprangers M; Vignetti M; Mandelli F
    Cancer; 2018 Mar; 124(6):1251-1259. PubMed ID: 29231969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of risk groups in myelodysplastic syndromes. A multicenter study.
    Belli C; Acevedo S; Bengio R; Arrossagaray G; Watman N; Rossi N; García J; Flores G; Goldztein S; Larripa I
    Haematologica; 2002 Jan; 87(1):9-16. PubMed ID: 11801460
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic Scoring System: validation by the Gruppo Romano Mielodisplasie Italian Regional Database.
    Voso MT; Fenu S; Latagliata R; Buccisano F; Piciocchi A; Aloe-Spiriti MA; Breccia M; Criscuolo M; Andriani A; Mancini S; Niscola P; Naso V; Nobile C; Piccioni AL; D'Andrea M; D'Addosio A; Leone G; Venditti A
    J Clin Oncol; 2013 Jul; 31(21):2671-7. PubMed ID: 23796988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical implications of copy number alteration detection using panel-based next-generation sequencing data in myelodysplastic syndrome.
    Kim YJ; Jung SH; Hur EH; Choi EJ; Lee KH; Park HC; Kim HJ; Kwon YR; Park S; Lee SH; Chung YJ; Lee JH
    Leuk Res; 2021 Apr; 103():106540. PubMed ID: 33667811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.